Margareta Correia

Dr. Margareta Correia

IPO Porto
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
MBMatthias Bozza
Matthias Bozza
ARAlice De Roia
Alice De Roia
MCMargareta Correia
Margareta Correia
ABAileen Berger
Aileen Berger
ATAlexandra Tuch
Alexandra Tuch
RHRichard Harbottle
Richard Harbottle
Autosomally replicating episomal DNA nanovectors allow clinical-scale CAR-T cell manufacturing.

9 January 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
CMCláudia Martins-Lima
Cláudia Martins-Lima
UCUgo Chianese
Ugo Chianese
RBRosaria Benedetti
Rosaria Benedetti
LALucia Altucci
Lucia Altucci
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
MCMargareta Correia
Margareta Correia
Bladder cancer (BlCa) is a highly immunogenic cancer. Bacillus Calmette-Guérin (BCG) is the standard treatment for non-muscle invasive bladder cancer (NMIBC) patients and, recently, second-line immunotherapies have arisen to treat metastatic BlCa patients. Understanding the interactions between tumor cells, immune cells and soluble factors in bladder tumor microenvironment (TME) is crucial. Cytokines and chemokines released in the TME have a dual role, since they can exhibit both a pro-inflammatory and anti-inflammatory potential, driving infiltration and inflammation, and also promoting evasion of immune system and pro-tumoral effects. In BlCa disease, 70–80% are non-muscle invasive bladder cancer, while 20–30% are muscle-invasive bladder cancer (MIBC) at the time of diagnosis. However, during the follow up, about half of treated NMIBC patients recur once or more, with 5–25% progressing to muscle-invasive bladder cancer, which represents a significant concern to the clinic. Epithelial-mesenchymal transition (EMT) is one biological process associated with tumor progression. Specific cytokines present in bladder TME have been related with signaling pathways activation and EMT-related molecules regulation. In this review, we summarized the immune landscape in BlCa TME, along with the most relevant cytokines and their putative role in driving EMT processes, tumor progression, invasion, migration and metastasis formation.

30 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
FRFilipa D. dos Reis
Filipa D. dos Reis
YSYanis Saidani
Yanis Saidani
PMPaula Martín-Rubio
Paula Martín-Rubio
RSRebeca Sanz-Pamplona
Rebeca Sanz-Pamplona
ASAna Stojanovic
Ana Stojanovic
MCMargareta Correia
Margareta Correia
Generation of Chimeric Antigen Receptors (CARs) presented a significant advance in the field of immunotherapy, allowing the targeting of cell-surface expressed molecules in an MHC-independent manner. Arming NK cells with CARs merges their innate natural cytotoxicity with the refined precision of targeted antigen recognition. The success of these therapies hinges on selecting the right tumor-specific targets to ensure effective activation and avoid self-reactivity. Optimization of CAR design and targeting is based on NK cell intrinsic properties (CAR modules and sources of NK cells), as well as on NK-tumor cell interactions (multi-antigen, multi-step, multi-switch). Additionally, the dynamics of tumor infiltration and adaptation to the tumor microenvironment play a critical role in CAR-NK cell efficacy. Combining CAR-NK cell therapies with chemotherapy, radiotherapy, checkpoint inhibitors, and emerging approaches like epigenetic modulators and oncolytic viruses, may address some of these challenges. The development of CAR-NK cell strategies for metastatic disease is especially promising, though the complexities of metastasis require refined targeted designs. As immunomics and multi-omics continue to evolve, the potential for designing more effective CAR-NK cell therapies expands. As results from preclinical and clinical trials unfold, a multidisciplinary approach integrating all those aspects will be key to unlock the full potential of CAR-NK cell-based adoptive transfers.

13 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
VCVânia Camilo
Vânia Camilo
NLNair Lopes
Nair Lopes
FMFilipa Moreira-Silva
Filipa Moreira-Silva
MCMargareta Correia
Margareta Correia
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Among the well-established alterations contributing to prostate cancer (PCa) pathogenesis, epigenetics is an important player in its development and aggressive disease state. Moreover, since no curative therapies are available for advanced stage disease, there is an urgent need for novel therapeutic strategies targeting this subset of patients. Thus, we aimed to evaluate the combined antineoplastic effects of DNA methylation inhibitor hydralazine and histone deacetylase inhibitors panobinostat and valproic acid in several prostate cell lines. The effect of these drugs was assessed in four PCa (LNCaP, 22Rv1, DU145 and PC-3) cell lines, as well as in non-malignant epithelial (RWPE-1) and stromal (WPMY-1) cell lines, using several assays to evaluate cell viability, apoptosis, proliferation, DNA damage and clonogenic potential. We found that exposure to each epidrug separately reduced viability of all PCa cells in a dose-dependent manner and that combined treatments led to synergic growth inhibitory effects, impacting also on colony formation, invasion, apoptotic and proliferation rates. Interestingly, antitumoral effects of combined treatment were particularly expressive in DU145 cells. We concluded that hydralazine and panobinostat attenuate malignant properties of PCa cells, constituting a potential therapeutic tool to counteract PCa progression.

19 January 2022 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
CGCatarina Guimarães‐Teixeira
Catarina Guimarães‐Teixeira
João LoboJoão Lobo
João Lobo
VMVera Miranda-Gonçalves
Vera Miranda-Gonçalves
DSDaniela Barros Silva
Daniela Barros Silva
CMCláudia Martins‐Lima
Cláudia Martins‐Lima
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
N6‐methyladenosine (m6A) and its regulatory proteins have been associated with tumorigenesis in several cancer types. However, knowledge on the mechanistic network related to m6A in bladder cancer (BlCa) is rather limited, requiring further investigation of its functional role. We aimed to uncover the biological role of m6A and related proteins in BlCa and understand how this influences tumor aggressiveness. N6‐adenosine‐methyltransferase catalytic subunit (METTL3), N6‐adenosine‐methyltransferase noncatalytic subunit (METTL14), protein virilizer homolog (VIRMA), and RNA demethylase ALKBH5 (ALKBH5) had significantly lower expression levels in BlCa compared to that in normal urothelium. METTL14 knockdown led to disruption of the remaining methyltransferase complex and a decrease in m6A abundance, as well as overall reduced tumor aggressiveness (decreased cell invasion and migration capacity and increased apoptosis). Furthermore, in vivo, METTL14 knockdown caused tumor size reduction. Collectively, we propose methyltransferase METTL14 as a key component for m6A RNA deposit and that it is closely related to BlCa progression, playing an important role in tumor aggressiveness. These data contribute to a better understanding of the m6A writer complex, which might constitute an appealing therapeutic target.

25 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FMFilipa Moreira-Silva
Filipa Moreira-Silva
GOGonçalo Outeiro-Pinho
Gonçalo Outeiro-Pinho
João LoboJoão Lobo
João Lobo
RGRita Guimarães
Rita Guimarães
Vítor GasparVítor Gaspar
Vítor Gaspar
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Castration-resistant prostate cancer (CRPC) is an incurable form of prostate cancer (PCa), with DNMT1 and G9a being reported as overexpressed, rendering them highly attractive targets for precision medicine. CM-272 is a dual inhibitor of both methyltransferases' activity. Herein, we assessed the response of different PCa cell lines to CM-272, in both 2D and 3D models, and explored the molecular mechanisms underlying CM-272 inhibitory effects. CRPC tissues displayed significantly higher DNMT1, G9a and H3K9me2 expression than localized PCa. In vitro, CM-272 caused a significant decrease in PCa cell viability and proliferation alongside with increased apoptotic levels. We disclose that, under the evaluated dose, CM-272 led to G9a activity inhibition, while not significantly affecting DNMT1 activity. Upon G9a knockdown, DU145 and PC3 showed decreased cell viability. Remarkably, DU145 cells treated with CM-272 or with G9a knockdown displayed no differences in viability, suggesting a SET-dependent mechanism. Contrarily, PC3 cell viability impact was higher in G9a knockdown, compared with CM-272 treatment, suggesting an additional G9a function. Moreover, DU145 cells overexpressing catalytically functional G9a disclosed higher resistance to CM-272 treatment, reinforcing that the drug mechanism of action is dependent on G9a catalytic function. Importantly, we successfully assembled spheroids from several prostate cell lines. Our results showed that CM-272 retained its anti-tumoral effects in 3D PCa models, leading to a clear reduction in cancer cell survival. We concluded that inhibition of G9a methyltransferase activity by CM-272 has anti-tumor effect in PCa cells, holding therapeutic potential against CRPC.